Cargando…

Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study

BACKGROUND: Impact of gender on time to initiation, response to and risk of modification of highly active antiretroviral therapy (HAART) in HIV-1 infected individuals is still controversial. METHODS: From a nationwide cohort of Danish HIV infected individuals we identified all heterosexually infecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Thorsteinsson, Kristina, Ladelund, Steen, Jensen-Fangel, Søren, Johansen, Isik Somuncu, Katzenstein, Terese L, Pedersen, Gitte, Storgaard, Merete, Obel, Niels, Lebech, Anne-Mette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532129/
https://www.ncbi.nlm.nih.gov/pubmed/23140254
http://dx.doi.org/10.1186/1471-2334-12-293
_version_ 1782254255550234624
author Thorsteinsson, Kristina
Ladelund, Steen
Jensen-Fangel, Søren
Johansen, Isik Somuncu
Katzenstein, Terese L
Pedersen, Gitte
Storgaard, Merete
Obel, Niels
Lebech, Anne-Mette
author_facet Thorsteinsson, Kristina
Ladelund, Steen
Jensen-Fangel, Søren
Johansen, Isik Somuncu
Katzenstein, Terese L
Pedersen, Gitte
Storgaard, Merete
Obel, Niels
Lebech, Anne-Mette
author_sort Thorsteinsson, Kristina
collection PubMed
description BACKGROUND: Impact of gender on time to initiation, response to and risk of modification of highly active antiretroviral therapy (HAART) in HIV-1 infected individuals is still controversial. METHODS: From a nationwide cohort of Danish HIV infected individuals we identified all heterosexually infected women (N=587) and heterosexually infected men (N=583) with no record of Hepatitis C infection diagnosed with HIV after 1 January 1997. Among these subjects, 473 women (81%) and 435 men (75%) initiated HAART from 1 January 1997 to 31 December 2009. We used Cox regression to calculate hazard ratio (HR) for time to initiation of HAART, Poisson regression to assess incidence rate ratios (IRR) of risk of treatment modification the first year, logistic regression to estimate differences in the proportion with an undetectable viral load, and linear regression to detect differences in CD4 count at year 1, 3 and 6 after start of HAART. RESULTS: At initiation of HAART, women were younger, predominantly of Black ethnicity and had a higher CD4 count (adjusted p=0.026) and lower viral load (adjusted p=0.0003). When repeating the analysis excluding pregnant women no difference was seen in CD4 counts (adjusted p=0.21). We observed no delay in time to initiation of HAART in women compared to men (HR 0.91, 95% CI 0.79-1.06). There were no gender differences in risk of treatment modification of the original HAART regimen during the first year of therapy for either toxicity (IRR 0.97 95% CI 0.66-1.44) or other/unknown reasons (IRR 1.18 95% CI 0.76-1.82). Finally, CD4 counts and the risk of having a detectable viral load at 1, 3 and 6 years did not differ between genders. CONCLUSIONS: In a setting with free access to healthcare and HAART, gender does neither affect time from eligibility to HAART, modification of therapy nor virological and immunological response to HAART. Differences observed between genders are mainly attributable to initiation of HAART in pregnant women.
format Online
Article
Text
id pubmed-3532129
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35321292013-01-03 Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study Thorsteinsson, Kristina Ladelund, Steen Jensen-Fangel, Søren Johansen, Isik Somuncu Katzenstein, Terese L Pedersen, Gitte Storgaard, Merete Obel, Niels Lebech, Anne-Mette BMC Infect Dis Research Article BACKGROUND: Impact of gender on time to initiation, response to and risk of modification of highly active antiretroviral therapy (HAART) in HIV-1 infected individuals is still controversial. METHODS: From a nationwide cohort of Danish HIV infected individuals we identified all heterosexually infected women (N=587) and heterosexually infected men (N=583) with no record of Hepatitis C infection diagnosed with HIV after 1 January 1997. Among these subjects, 473 women (81%) and 435 men (75%) initiated HAART from 1 January 1997 to 31 December 2009. We used Cox regression to calculate hazard ratio (HR) for time to initiation of HAART, Poisson regression to assess incidence rate ratios (IRR) of risk of treatment modification the first year, logistic regression to estimate differences in the proportion with an undetectable viral load, and linear regression to detect differences in CD4 count at year 1, 3 and 6 after start of HAART. RESULTS: At initiation of HAART, women were younger, predominantly of Black ethnicity and had a higher CD4 count (adjusted p=0.026) and lower viral load (adjusted p=0.0003). When repeating the analysis excluding pregnant women no difference was seen in CD4 counts (adjusted p=0.21). We observed no delay in time to initiation of HAART in women compared to men (HR 0.91, 95% CI 0.79-1.06). There were no gender differences in risk of treatment modification of the original HAART regimen during the first year of therapy for either toxicity (IRR 0.97 95% CI 0.66-1.44) or other/unknown reasons (IRR 1.18 95% CI 0.76-1.82). Finally, CD4 counts and the risk of having a detectable viral load at 1, 3 and 6 years did not differ between genders. CONCLUSIONS: In a setting with free access to healthcare and HAART, gender does neither affect time from eligibility to HAART, modification of therapy nor virological and immunological response to HAART. Differences observed between genders are mainly attributable to initiation of HAART in pregnant women. BioMed Central 2012-11-12 /pmc/articles/PMC3532129/ /pubmed/23140254 http://dx.doi.org/10.1186/1471-2334-12-293 Text en Copyright ©2012 Thorsteinsson et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Thorsteinsson, Kristina
Ladelund, Steen
Jensen-Fangel, Søren
Johansen, Isik Somuncu
Katzenstein, Terese L
Pedersen, Gitte
Storgaard, Merete
Obel, Niels
Lebech, Anne-Mette
Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study
title Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study
title_full Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study
title_fullStr Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study
title_full_unstemmed Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study
title_short Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study
title_sort impact of gender on response to highly active antiretroviral therapy in hiv-1 infected patients: a nationwide population-based cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532129/
https://www.ncbi.nlm.nih.gov/pubmed/23140254
http://dx.doi.org/10.1186/1471-2334-12-293
work_keys_str_mv AT thorsteinssonkristina impactofgenderonresponsetohighlyactiveantiretroviraltherapyinhiv1infectedpatientsanationwidepopulationbasedcohortstudy
AT ladelundsteen impactofgenderonresponsetohighlyactiveantiretroviraltherapyinhiv1infectedpatientsanationwidepopulationbasedcohortstudy
AT jensenfangelsøren impactofgenderonresponsetohighlyactiveantiretroviraltherapyinhiv1infectedpatientsanationwidepopulationbasedcohortstudy
AT johansenisiksomuncu impactofgenderonresponsetohighlyactiveantiretroviraltherapyinhiv1infectedpatientsanationwidepopulationbasedcohortstudy
AT katzensteinteresel impactofgenderonresponsetohighlyactiveantiretroviraltherapyinhiv1infectedpatientsanationwidepopulationbasedcohortstudy
AT pedersengitte impactofgenderonresponsetohighlyactiveantiretroviraltherapyinhiv1infectedpatientsanationwidepopulationbasedcohortstudy
AT storgaardmerete impactofgenderonresponsetohighlyactiveantiretroviraltherapyinhiv1infectedpatientsanationwidepopulationbasedcohortstudy
AT obelniels impactofgenderonresponsetohighlyactiveantiretroviraltherapyinhiv1infectedpatientsanationwidepopulationbasedcohortstudy
AT lebechannemette impactofgenderonresponsetohighlyactiveantiretroviraltherapyinhiv1infectedpatientsanationwidepopulationbasedcohortstudy